Neogenomics Stock Investor Sentiment
| NEO Stock | USD 9.82 0.30 3.15% |
About 61% of all NeoGenomics' investors are looking to take a long position. The analysis of overall sentiment of trading NeoGenomics stock suggests that some investors are interested at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 61
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use NeoGenomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward NeoGenomics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentWaiting |
NeoGenomics Historical Sentiment
Although NeoGenomics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding NeoGenomics, such as negative comments on social media and news outlets, may cause fear in the market and push NeoGenomics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of NeoGenomics.
NeoGenomics |
NeoGenomics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NeoGenomics Historical Investor Sentiment
Investor biases related to NeoGenomics' public news can be used to forecast risks associated with an investment in NeoGenomics. The trend in average sentiment can be used to explain how an investor holding NeoGenomics can time the market purely based on public headlines and social activities around NeoGenomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
NeoGenomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for NeoGenomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average NeoGenomics news discussions. The higher the estimate score, the more favorable the investor's outlook on NeoGenomics.
NeoGenomics Maximum Pain Price Across May 16th 2025 Option Contracts
NeoGenomics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of NeoGenomics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of NeoGenomics' options.
Far too much social signal, news, headlines, and media speculation about NeoGenomics that are available to investors today. That information is available publicly through NeoGenomics media outlets and privately through word of mouth or via NeoGenomics internal channels. However, regardless of the origin, that massive amount of NeoGenomics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeoGenomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeoGenomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeoGenomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeoGenomics alpha.
NeoGenomics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 7070 shares by Harris Melody of NeoGenomics subject to Rule 16b-3 | 12/31/2024 |
2 | NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference | 01/06/2025 |
3 | Acquisition by Williams Felicia of 5430 shares of NeoGenomics at 13.59 subject to Rule 16b-3 | 01/22/2025 |
4 | NeoGenomics Stock Declines Amid Weak Q4 Results | 02/18/2025 |
5 | NeoGenomics Inc Q4 2024 Earnings Call Highlights Strong Revenue Growth and Strategic ... | 02/19/2025 |
6 | Wyloo to form Yangibana Joint Venture with Hastings and becomes largest shareholder in Neo Performance Materials | 02/20/2025 |
7 | Disposition of 57413 shares by Smith Christopher M of NeoGenomics subject to Rule 16b-3 | 02/21/2025 |
8 | NeoGenomics to Participate in Upcoming Investor Conferences | 02/24/2025 |
9 | Disposition of 11336 shares by Zook Anthony P. of NeoGenomics subject to Rule 16b-3 | 02/27/2025 |
10 | Disposition of 5175 shares by Alicia Olivo of NeoGenomics at 15.3575 subject to Rule 16b-3 | 03/13/2025 |
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.62) | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.